Clinical Trials on Genital Psoriasis in Switzerland

Total 5139 results

Novartis Pharmaceuticals

Completed

A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis

Plaque Psoriasis, Psoriatic Arthritis

Switzerland
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
Novartis Pharmaceuticals

Completed

Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry

Psoriasis | Psoriatic Arthritis

Switzerland
Ennar Pharmaceuticals AF
University of Zurich

Unknown

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF (EGFR)

Plaque Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Moderate to Severe Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

Switzerland
Merck KGaA, Darmstadt, Germany

Completed

A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis | Candidates for Systemic Therapy for Psoriasis

Switzerland
University of Zurich

Unknown

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis (APRESCALP)

Psoriasis Vulgaris | Psoriasis of Scalp

Switzerland
University of Zurich

Withdrawn

Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis (DIPSO)

Psoriasis

Switzerland
Immune Technologies & Medicine GmbH

Unknown

Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis

Psoriasis

Switzerland
University of Zurich

Completed

Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases (PRUVAB)

Psoriasis | Eczema

Switzerland
Prof Curdin Conrad
Centre Hospitalier Universitaire Vaudois

Not yet recruiting

TYK2 Inhibition in Paradoxical Psoriasis (TYPP)

Psoriasis

Switzerland
UCB Biopharma SRL

Completed

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (CHERISH)

Rheumatoid Arthritis | Plaque Psoriasis | Crohn's Disease | Psoriatic Arthritis | Axial Spondyloarthritis

United States, France, Germany, Spain, Switzerland, Netherlands
University Hospital, Basel, Switzerland
Boehringer Ingelheim

Recruiting

International Rare And Severe Psoriasis Expert Network (IRASPEN)

Pustular Psoriasis (PP)

Germany, Italy, Singapore, Switzerland, Portugal, Turkey
Amgen

Completed

A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis (MOSAIC)

Psoriatic Arthritis

Spain, Belgium, Denmark, United States, Germany, Russian Federation, Austria, United Kingdom, Canada, Italy, Switzerland
Centocor, Inc.

Completed

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada, Switzerland, Finland, Denmark
Permedica spa

Active, not recruiting

Follow-up Evaluating Clinical and Radiological Outcomes of Total Shoulder Arthroplasty With Permedica's MIRAI Prosthesis

Psoriatic Arthritis | Shoulder Osteoarthritis | Primary Osteoarthritis | Secondary Osteoarthritis | Avascular Necrosis of Humerus | Rheumatoid Arthritis Shoulder | Cuff Tear Arthropathy | Fracture, Shoulder

Germany, Italy, Switzerland
Amgen

Completed

PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE 3)

Psoriatic Arthritis

United States, United Kingdom, Korea, Republic of, Spain, Germany, Switzerland, Slovakia, Australia, Poland, Russian Federation, Italy, Finland, Canada, Romania, Lithuania, France
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (CRADLE)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

United States, Netherlands, Switzerland
Swiss Dermatology Network for Targeted Therapies

Recruiting

Swiss Dermatology Network of Targeted Therapies (SDNTT) (SDNTT)

Psoriasis

Switzerland
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Novartis Pharmaceuticals

Completed

Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement (MAXIMISE)

Axial Psoratic Arthritis

Belgium, Israel, Spain, Switzerland, Greece, Italy, Bulgaria, Germany, Hungary, Estonia, United Kingdom, Poland, France, Czechia, Russian Federation, Romania, Ireland, Finland
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis (SPIRIT-H2H)

Psoriatic Arthritis

Belgium, Hungary, Canada, India, Israel, Italy, Australia, Netherlands, United Kingdom, Mexico, Switzerland, South Africa, Poland, Finland, Argentina, France, Germany, Ukraine, Spain, Austria, Denmark, Sweden
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis

Psoriatic Arthritis

France, Belgium, Korea, Republic of, Netherlands, United Kingdom, Germany, Taiwan, Portugal, Denmark, Saudi Arabia, Czechia, Sweden, Switzerland, Argentina, Poland, Italy, Hungary, Spain, Australia, Austria, Colombia, Finland, Former... and more
UCB BIOSCIENCES, Inc.
PPD; Parexel

Completed

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta (CRIB)

Rheumatoid Arthritis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Non-radiographic Evidence-AxSpA

Netherlands, Switzerland, United States, France
Boehringer Ingelheim

Completed

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Generalized Pustular Psoriasis

United States, Singapore, Korea, Republic of, Germany, Japan, Malaysia, China, France, Thailand, Tunisia, Switzerland, Taiwan
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
University of Zurich

Unknown

Haut-Tief Patient Education on Psoriasis and Eczema

Psoriasis | Atopic Dermatitis/ Eczema

Switzerland
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Active, not recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

United Kingdom, Korea, Republic of, France, Belgium, Japan, Taiwan, Austria, Canada, Netherlands, Spain, Italy, Germany, Australia, Switzerland, Mexico, Sweden, Greece, Argentina, Colombia, Russian Federation
Novartis Pharmaceuticals

Completed

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (STEPin)

Plaque Psoriasis

Spain, United Kingdom, Estonia, Germany, Bulgaria, Finland, Hungary, Poland, Argentina, Canada, Denmark, Switzerland, Sweden
Amgen

Completed

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. (ESTEEM 2)

Plaque Psoriasis

Spain, United States, Canada, Germany, Denmark, France, Italy, Switzerland, Austria
Creabilis SA

Completed

CT 327 in the Treatment of Psoriasis Vulgaris

Psoriasis

Switzerland, United States, United Kingdom
Eli Lilly and Company

Active, not recruiting

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Juvenile Psoriatic Arthritis | Enthesitis Related Arthritis

Spain, Belgium, Germany, Italy, United Kingdom, Denmark, Mexico, Netherlands, Switzerland
Biogen

Completed

Safety and Tolerability of Repeat Courses of IM Alefacept

Chronic Plaque Psoriasis

United States, Germany, France, Canada, Austria, Denmark, Netherlands, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Janssen-Cilag International NV

Recruiting

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis (STELARA)

Psoriasis

Belgium, United Kingdom, Austria, Denmark, France, Germany, Netherlands, Norway, Russian Federation, Switzerland, Greece
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Amgen

Completed

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life (EMBRACE)

Psoriasis

France, Italy, Spain, United Kingdom, Switzerland, Germany

Clinical Trials on Genital Psoriasis in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations